- •Preface
- •List of contributers
- •History, epidemiology, prevention and education
- •A history of burn care
- •“Black sheep in surgical wards”
- •Toxaemia, plasmarrhea, or infection?
- •The Guinea Pig Club
- •Burns and sulfa drugs at Pearl Harbor
- •Burn center concept
- •Shock and resuscitation
- •Wound care and infection
- •Burn surgery
- •Inhalation injury and pulmonary care
- •Nutrition and the “Universal Trauma Model”
- •Rehabilitation
- •Conclusions
- •References
- •Epidemiology and prevention of burns throughout the world
- •Introduction
- •Epidemiology
- •The inequitable distribution of burns
- •Cost by age
- •Cost by mechanism
- •Limitations of data
- •Risk factors
- •Socioeconomic factors
- •Race and ethnicity
- •Age-related factors: children
- •Age-related factors: the elderly
- •Regional factors
- •Gender-related factors
- •Intent
- •Comorbidity
- •Agents
- •Non-electric domestic appliances
- •War, mass casualties, and terrorism
- •Interventions
- •Smoke detectors
- •Residential sprinklers
- •Hot water temperature regulation
- •Lamps and stoves
- •Fireworks legislation
- •Fire-safe cigarettes
- •Children’s sleepwear
- •Acid assaults
- •Burn care systems
- •Role of the World Health Organization
- •Conclusions and recommendations
- •Surveillance
- •Smoke alarms
- •Gender inequality
- •Community surveys
- •Acknowledgements
- •References
- •Prevention of burn injuries
- •Introduction
- •Burns prevalence and relevance
- •Burn injury risk factors
- •WHERE?
- •Burn prevention types
- •Burn prevention: The basics to design a plan
- •Flame burns
- •Prevention of scald burns
- •Conclusions
- •References
- •Burns associated with wars and disasters
- •Introduction
- •Wartime burns
- •Epidemiology of burns sustained during combat operations
- •Fluid resuscitation and initial burn care in theater
- •Evacuation of thermally-injured combat casualties
- •Care of host-nation burn patients
- •Disaster-related burns
- •Epidemiology
- •Treatment of disaster-related burns
- •The American Burn Association (ABA) disaster management plan
- •Summary
- •References
- •Education in burns
- •Introduction
- •Surgical education
- •Background
- •Simulation
- •Education in the internet era
- •Rotations as courses
- •Mentorship
- •Peer mentorship
- •Hierarchical mentorship
- •What is a mentor
- •Implementation
- •Interprofessional education
- •What is interprofessional education
- •Approaches to interprofessional education
- •References
- •European practice guidelines for burn care: Minimum level of burn care provision in Europe
- •Foreword
- •Background
- •Introduction
- •Burn injury and burn care in general
- •Conclusion
- •References
- •Pre-hospital and initial management of burns
- •Introduction
- •Modern care
- •Early management
- •At the accident
- •At a local hospital – stabilization prior to transport to the Burn Center
- •Transportation
- •References
- •Medical documentation of burn injuries
- •Introduction
- •Medical documentation of burn injuries
- •Contents of an up-to-date burns registry
- •Shortcomings in existing documentation systems designs
- •Burn depth
- •Burn depth as a dynamic process
- •Non-clinical methods to classify burn depth
- •Burn extent
- •Basic principles of determining the burn extent
- •Methods to determine burn extent
- •Computer aided three-dimensional documentation systems
- •Methods used by BurnCase 3D
- •Creating a comparable international database
- •Results
- •Conclusion
- •Financing and accomplishment
- •References
- •Pathophysiology of burn injury
- •Introduction
- •Local changes
- •Burn depth
- •Burn size
- •Systemic changes
- •Hypovolemia and rapid edema formation
- •Altered cellular membranes and cellular edema
- •Mediators of burn injury
- •Hemodynamic consequences of acute burns
- •Hypermetabolic response to burn injury
- •Glucose metabolism
- •Myocardial dysfunction
- •Effects on the renal system
- •Effects on the gastrointestinal system
- •Effects on the immune system
- •Summary and conclusion
- •References
- •Anesthesia for patients with acute burn injuries
- •Introduction
- •Preoperative evaluation
- •Monitors
- •Pharmacology
- •Postoperative care
- •References
- •Diagnosis and management of inhalation injury
- •Introduction
- •Effects of inhaled gases
- •Carbon monoxide
- •Cyanide toxicity
- •Upper airway injury
- •Lower airway injury
- •Diagnosis
- •Resuscitation after inhalation injury
- •Other treatment issues
- •Prognosis
- •Conclusions
- •References
- •Respiratory management
- •Airway management
- •(a) Endotracheal intubation
- •(b) Elective tracheostomy
- •Chest escharotomy
- •Conventional mechanical ventilation
- •Introduction
- •Pathophysiological principles
- •Low tidal volume and limited plateau pressure approaches
- •Permissive hypercapnia
- •The open-lung approach
- •PEEP
- •Lung recruitment maneuvers
- •Unconventional mechanical ventilation strategies
- •High-frequency percussive ventilation (HFPV)
- •High-frequency oscillatory ventilation
- •Airway pressure release ventilation (APRV)
- •Ventilator associated pneumonia (VAP)
- •(a) Prevention
- •(b) Treatment
- •References
- •Organ responses and organ support
- •Introduction
- •Burn shock and resuscitation
- •Post-burn hypermetabolism
- •Individual organ systems
- •Central nervous system
- •Peripheral nervous system
- •Pulmonary
- •Cardiovascular
- •Renal
- •Gastrointestinal tract
- •Conclusion
- •References
- •Critical care of thermally injured patient
- •Introduction
- •Oxidative stress control strategies
- •Fluid and cardiovascular management beyond 24 hours
- •Other organ function/dysfunction and support
- •The nervous system
- •Respiratory system and inhalation injury
- •Renal failure and renal replacement therapy
- •Gastro-intestinal system
- •Glucose control
- •Endocrine changes
- •Stress response (Fig. 2)
- •Low T3 syndrome
- •Gonadal depression
- •Thermal regulation
- •Metabolic modulation
- •Propranolol
- •Oxandrolone
- •Recombinant human growth hormone
- •Insulin
- •Electrolyte disorders
- •Sodium
- •Chloride
- •Calcium, phosphate and magnesium
- •Calcium
- •Bone demineralization and osteoporosis
- •Micronutrients and antioxidants
- •Thrombosis prophylaxis
- •Conclusion
- •References
- •Treatment of infection in burns
- •Introduction
- •Clinical management strategies
- •Pathophysiology of the burn wound
- •Burn wound infection
- •Cellulitis
- •Impetigo
- •Catheter related infections
- •Urinary tract infection
- •Tracheobronchitis
- •Pneumonia
- •Sepsis in the burn patient
- •The microbiology of burn wound infection
- •Sources of organisms
- •Gram-positive organisms
- •Gram-negative organisms
- •Infection control
- •Pharmacological considerations in the treatment of burn infections
- •Topical antimicrobial treatment
- •Systemic antimicrobial treatment (Table 3)
- •Gram-positive bacterial infections
- •Enterococcal bacterial infections
- •Gram-negative bacterial infections
- •Treatment of yeast and fungal infections
- •The Polyenes (Amphotericin B)
- •Azole antifungals
- •Echinocandin antifungals
- •Nucleoside analog antifungal (Flucytosine)
- •Conclusion
- •References
- •Acute treatment of severely burned pediatric patients
- •Introduction
- •Initial management of the burned child
- •Fluid resuscitation
- •Sepsis
- •Inhalation injury
- •Burn wound excision
- •Burn wound coverage
- •Metabolic response and nutritional support
- •Modulation of the hormonal and endocrine response
- •Recombinant human growth hormone
- •Insulin-like growth factor
- •Oxandrolone
- •Propranolol
- •Glucose control
- •Insulin
- •Metformin
- •Novel therapeutic options
- •Long-term responses
- •Conclusion
- •References
- •Adult burn management
- •Introduction
- •Epidemiology and aetiology
- •Pathophysiology
- •Assessment of the burn wound
- •Depth of burn
- •Size of the burn
- •Initial management of the burn wound
- •First aid
- •Burn blisters
- •Escharotomy
- •General care of the adult burn patient
- •Biological/Semi biological dressings
- •Topical antimicrobials
- •Biological dressings
- •Other dressings
- •Exposure
- •Deep partial thickness wound
- •Total wound excision
- •Serial wound excision and conservative management
- •Full thickness burns
- •Excision and autografting
- •Topical antimicrobials
- •Large full thickness burns
- •Serial excision
- •Mixed depth burn
- •Donor sites
- •Techniques of wound excision
- •Blood loss
- •Antibiotics
- •Anatomical considerations
- •Skin replacement
- •Autograft
- •Allograft
- •Other skin replacements
- •Cultured skin substitutes
- •Skin graft take
- •Rehabilitation and outcome
- •Future care
- •References
- •Burns in older adults
- •Introduction
- •Burn injury epidemiology
- •Pathophysiologic changes and implications for burn therapy
- •Aging
- •Comorbidities
- •Acute management challenges
- •Fluid resuscitation
- •Burn excision
- •Pain and sedation
- •End of life decisions
- •Summary of key points and recommendations
- •References
- •Acute management of facial burns
- •Introduction
- •Anatomy and pathophysiology
- •Management
- •General approach
- •Airway management
- •Facial burn wound management
- •Initial wound care
- •Topical agents
- •Biological dressings
- •Surgical burn wound excision of the face
- •Wound closure
- •Special areas and adjacent of the face
- •Eyelids
- •Nose and ears
- •Lips
- •Scalp
- •The neck
- •Catastrophic injury
- •Post healing rehabilitation and scar management
- •Outcome and reconstruction
- •Summary
- •References
- •Hand burns
- •Introduction
- •Initial evaluation and history
- •Initial wound management
- •Escharotomy and fasciotomy
- •Surgical management: Early excision and grafting
- •Skin substitutes
- •Amputation
- •Hand therapy
- •Secondary reconstruction
- •References
- •Treatment of burns – established and novel technology
- •Introduction
- •Partial thickness burns
- •Biological membranes – amnion and others
- •Xenograft
- •Full thickness burns
- •Dermal analogs
- •Keratinocyte coverage
- •Facial transplantation
- •Tissue engineering and stem cells
- •Gene therapy and growth factors
- •Conclusion
- •References
- •Wound healing
- •History of wound care
- •Types of wounds
- •Mechanisms of wound healing
- •Hemostasis
- •Proliferation
- •Epithelialization
- •Remodeling
- •Fetal wound healing
- •Stem cells
- •Abnormal wound healing
- •Impaired wound healing
- •Hypertrophic scars and keloids
- •Chronic non-healing wounds
- •Conclusions
- •References
- •Pain management after burn trauma
- •Introduction
- •Pathophysiology of pain after burn injuries
- •Nociceptive pain
- •Neuropathic pain
- •Sympathetically Maintained Pain (SMP)
- •Pain rating and documentation
- •Pain management and analgesics
- •Pharmacokinetics in severe burns
- •Form of administration [21]
- •Non-opioids (Table 1)
- •Paracetamol
- •Metamizole
- •Non-steroidal antirheumatics (NSAID)
- •Selective cyclooxygenasis-2-inhibitors
- •Opioids (Table 2)
- •Weak opioids
- •Strong opioids
- •Other analgesics
- •Ketamine (see also intensive care unit and analgosedation)
- •Anticonvulsants (Gabapentin and Pregabalin)
- •Antidepressants with analgesic effects
- •Regional anesthesia
- •Pain management without analgesics
- •Adequate communication
- •Psychological techniques [65]
- •Transcutaneous electrical nerve stimulation (TENS)
- •Particularities of burn pain
- •Wound pain
- •Breakthrough pain
- •Intervention-induced pain
- •Necrosectomy and skin grafting
- •Dressing change of large burn wounds and removal of clamps in skin grafts
- •Dressing change in smaller burn wounds, baths and physical therapy
- •Postoperative pain
- •Mental aspects
- •Intensive care unit
- •Opioid-induced hyperalgesia and opioid tolerance
- •Hypermetabolism
- •Psychic stress factors
- •Risk of infection
- •Monitoring [92]
- •Sedation monitoring
- •Analgesia monitoring (see Fig. 2)
- •Analgosedation (Table 3)
- •Sedation
- •Analgesia
- •References
- •Nutrition support for the burn patient
- •Background
- •Case presentation
- •Patient selection: Timing and route of nutritional support
- •Determining nutritional demands
- •What is an appropriate initial nutrition plan for this patient?
- •Formulations for nutritional support
- •Monitoring nutrition support
- •Optimal monitoring of nutritional status
- •Problems and complications of nutritional support
- •Conclusion
- •References
- •HBO and burns
- •Historical development
- •Contraindications for the use of HBO
- •Conclusion
- •References
- •Nursing management of the burn-injured person
- •Introduction
- •Incidence
- •Prevention
- •Pathophysiology
- •Severity factors
- •Local damage
- •Fluid and electrolyte shifts
- •Cardiovascular, gastrointestinal and renal system manifestations
- •Types of burn injuries
- •Thermal
- •Chemical
- •Electrical
- •Smoke and inhalation injury
- •Clinical manifestations
- •Subjective symptoms
- •Possible complications
- •Clinical management
- •Non-surgical care
- •Surgical care
- •Coordination of care: Burn nursing’s unique role
- •Nursing interventions: Emergent phase
- •Nursing interventions: Acute phase
- •Nursing interventions: Rehabilitative phase
- •Ongoing care
- •Infection prevention and control
- •Rehabilitation medicine
- •Nutrition
- •Pharmacology
- •Conclusion
- •References
- •Outpatient burn care
- •Introduction
- •Epidemiology
- •Accident causes
- •Care structures
- •Indications for inpatient treatment
- •Patient age
- •Total burned body surface area (TBSA)
- •Depth of the burn
- •Pre-existing conditions
- •Accompanying injuries
- •Special injuries
- •Treatment
- •Initial treatment
- •Pain therapy
- •Local treatment
- •Course of treatment
- •Complications
- •Infections
- •Follow-up care
- •References
- •Non-thermal burns
- •Electrical injury
- •Introduction
- •Pathophysiology
- •Initial assessment and acute care
- •Wound care
- •Diagnosis
- •Low voltage injuries
- •Lightning injuries
- •Complications
- •References
- •Symptoms, diagnosis and treatment of chemical burns
- •Chemical burns
- •Decontamination
- •Affection of different organ systems
- •Respiratory tract
- •Gastrointestinal tract
- •Hematological signs
- •Nephrologic symptoms
- •Skin
- •Nitric acid
- •Sulfuric acid
- •Caustic soda
- •Phenol
- •Summary
- •References
- •Necrotizing and exfoliative diseases of the skin
- •Introduction
- •Necrotizing diseases of the skin
- •Cellulitis
- •Staphylococcal scalded skin syndrome
- •Autoimmune blistering diseases
- •Epidermolysis bullosa acquisita
- •Necrotizing fasciitis
- •Purpura fulminans
- •Exfoliative diseases of the skin
- •Stevens-Johnson syndrome
- •Toxic epidermal necrolysis
- •Conclusion
- •References
- •Frostbite
- •Mechanism
- •Risk factors
- •Causes
- •Diagnosis
- •Treatment
- •Rewarming
- •Surgery
- •Sympathectomy
- •Vasodilators
- •Escharotomy and fasciotomy
- •Prognosis
- •Research
- •References
- •Subject index
D. A. Brown, N. S. Gibran
Conclusions
Wound healing remains an integral element of modern surgical science, contributing to both the function and form of wounds in all surgical patients but especially those with burn injuries. The biology of wound healing entails many integrated, parallel processes that lead to decontamination and closure
of a wound. Restoration of tissue integrity relies on a careful balance between inflammation and proliferation, which is tipped in pathologic states of wound healing. Efforts are underway to unravel the mysteries of fetal wound repair and regeneration, which may lead to novel treatments for proliferative wounds or reduce scarring in normal adult wound healing.
Table 3. Examples of burn dressings, adapted from reference [91]. Products listed are registered trademarks: Jelonet , Opsite , Intrasite Gel , Allevyn , and Acticoat (Smith & Nephew UK Limited, London, UK); Atrauman (Hartmann, Homebush, Australia), Mepilex (Molnlycke, Norcross, GA), Tegaderm (3M, St. Paul, MN), Comfeel and Biatain Adhesive (Coloplast, Minneapolis, MN); DuoDERM , Granuflex , Aquacel , Versiva , Kaltostat , and Aquacel Ag , and Aquaform (ConvaTec, Skillman, NJ); Actisorb and Inadine (Johnson & Johnson, New Brunswick, NJ)
Dressing type |
Examples |
Clinical use |
Low adherence dressings |
Jelonet (Smith & Nephew) |
Superficial and partial thickness burns with |
|
Atrauman (Hartmann) |
minimal exudate |
|
Mepilex (Molnlycke) |
|
Semi-permeable films |
Opsite (Smith & Nephew) |
Superficial and partial thickness burns with |
|
Tegaderm (3M) |
minimal exudate |
Hydrocolloids |
Comfeel (Coloplast) |
Superficial and partial thickness burns in high |
|
DuoDERM (ConvaTec) |
range of motion areas |
|
Granuflex (ConvaTec) |
|
Hydrofibers |
Aquacel (ConvaTec) |
Partial thickness burns with moderate exudate |
|
Versiva ConvaTec) |
|
Hydrogels |
Aquaform (ConvaTec) |
Small deep partial thickness burns with slough |
|
Intrasite Gel (Smith & Nephew) |
|
Alginate |
Kaltostat (ConvaTec) |
Skin graft donor sites |
Foam/hydrocellular |
Allevyn (Smith & Nephew) |
Superficial and partial thickness burns with |
|
Biatain Adhesive (Coloplast) |
minimal exudate |
Antimicrobials |
Acticoat (Smith & Nephew) |
Superficial and partial thickness burns with |
|
Actisorb (Johnson & Johnson) |
moderate exudate and/or evidence of infection |
|
Aquacel Ag (ConvaTec) |
|
|
Inadine (Johnson & Johnson) |
|
|
Mepilex Ag (Molnyke) |
|
334
Wound healing
Table 4. Examples of skin substitutes for burns wounds, adapted from reference [92]. Oasis (Healthpoint LTD, San Antonio, TX), Transcyte (Advanced BioHealing, Westport, CT), Biobrane (Smith & Nephew UK Limited, London, UK), Apligraf (Organogenesis, Canton, MA), OrCel (Forticell Bioscience, Englewood Cliffs, NJ), Epicel (Genzyme, Cambridge, MA), and Alloderm (LifeCell, Branchburg, NJ), Integra (Integra Life Sciences, Plainsboro, NJ) are registered trademarks
Product |
Composition |
Clinical Uses |
Human allograft |
Cadaveric epidermis & dermis |
Temporary coverage of large excised burns |
Porcine xenograft |
Porcine dermis |
Temporary coverage of large excised burns |
Human |
Placental amniotic membrane |
Temporary coverage of large excised burns |
amnion |
|
|
Oasis |
Porcine intestine submucosa |
Superficial burns, skin graft donor sites, chronic wounds |
Biobrane |
Silicone and collagen-nylon bilayer |
Partial thickness burns, temporary coverage of excised |
|
|
burns |
Transcyte |
Allogenic dermis and silicone bilayer |
Partial thickness burns, temporary coverage of excised |
|
|
burns |
Apligraf |
Collagen matrix with human neonatal |
Permanent coverage of excised burns, chronic wounds |
|
fibroblasts and keratinocytes |
|
OrCel |
Collagen matrix with human neonatal |
Skin graft donor sites, chronic wounds |
|
fibroblasts and keratinocytes |
|
Epicel |
Cultured autologous keratinocytes |
Deep partial thickness and full thickness burns |
Alloderm |
Acellular human dermis |
Soft tissue defects |
Integra |
Silicone and collagen-glyco- |
Deep partial thickness and full thickness burns |
|
saminoglycan bilayer |
|
References
[1]Sipos P, Gyory H, Hagymasi K, Ondrejka P, Blazovics A (2004) Special wound healing methods used in ancient egypt and the mythological background. World J Surg
28:211–216
[2]Forrest RD (1982) Early history of wound treatment. J Roy Soc Med 75: 198–205
[3]Lederberg J (2000) Infectious history. Science 288: 287–293
[4]Kumar V, Abbas AK, Fausto N (2005) Robbins and Cotran pathologic basis of disease. Elsevier Saunders, Philadelphia
[5]Townsend CM (2007) Sabiston textbook of surgery: Expert consult: Online & Print. Saunders
[6]Lee RC (1997) Injury by electrical forces: pathophysiology, manifestations, and therapy. Curr Probl Surg
34:677
[7]Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T (2004) Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 140: 1037
[8]Foster K, Greenhalgh D, Gamelli RL, Mozingo D, Gibran N, Neumeister M, Abrams SZ, Hantak E, Grubbs L, Ploder B (2008) Efficacy and safety of a fibrin sealant
for adherence of autologous skin grafts to burn wounds: results of a phase 3 clinical study. J Burn Care Res
29:293
[9]Ramasastry SS (2005) Acute wounds. Clin Plast Surg
32:195–208
[10]Singer AJ, Clark RAF (1999) Cutaneous wound healing. N Engl J Med 341: 738
[11]Ley K (1992) Leukocyte adhesion to vascular endothelium. J Reconstr Microsurg 8: 495–495
[12]Leibovich SJ, Ross R (1975) The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 78: 71–100
[13]Nwomeh BC, Olutoye OO, Diegelmann RF, Cohen IK (1997) Biology of wound healing. J Surg Pathol 2: 1–19
[14]Murphy MA, Joyce WP, Condron C, Bouchier-Hayes D (2002) A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 23: 349–352
[15]Helme RD, Eglezos A, Hosking CS (1987) Substance P induces chemotaxis of neutrophils in normal and cap- saicin-treated rats. Immunol Cell Biol 65: 267–269
[16]Kavelaars A, Jeurissen F, Heijnen CJ (1994) Substance P receptors and signal transduction in leukocytes. Immunomethods 5: 41
[17]Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F (1994) Nitric oxide me-
335
D. A. Brown, N. S. Gibran
diates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94: 2036
[18]Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40: 264–278
[19]Paus R, Heinzelmann T, Robicsek S, Czarnetzki BM, Maurer M (1995) Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 287: 500–502
[20]Scott JR, Muangman PR, Tamura RN, Zhu KQ, Liang Z, Anthony J, Engrav LH, Gibran NS (2005) Substance P levels and neutral endopeptidase activity in acute burn wounds and hypertrophic scar. Plast Reconstr Surg 115: 1095
[21]Scott JR, Muangman P, Gibran NS (2007) Making sense of hypertrophic scar: a role for nerves. Wound Repair Regen 15:S27-S31
[22]Luster AD, Cardiff RD, MacLean JA, Crowe K, Granstein RD (1998) Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proceedings of the Association of American Physicians 110: 183
[23]Liechty KW, Adzick NS, Crombleholme TM (2000) Diminished interleukin 6 (IL-6) production during scarless human fetal wound repair. Cytokine 12: 671–676
[24]Spyrou GE, Naylor IL (2002) The effect of basic fibroblast growth factor on scarring. Br J Plast Surg 55: 275–282
[25]Rennekampff HO, Hansbrough JF, Kiessig V, Doré C, Sticherling M, Schröder JM (2000) Bioactive inter- leukin-8 is expressed in wounds and enhances wound healing. J Surg Res 93: 41–54
[26]Smith PD, Kuhn MA, Franz MG, Wachtel TL, Wright TE, Robson MC (2000) Initiating the inflammatory phase of incisional healing prior to tissue injury. J Surg Res 92: 11–17
[27]Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Gramates P, Deuel TF (1989) Transforming growth factor beta reverses the glucocorticoid-induced woundhealing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc Natl Acad Sci U S A 86: 2229
[28]Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A (2000) Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res 20: 143–152
[29]Gabriel VA (2009) Transforming growth factor-[beta] and angiotensin in fibrosis and burn injuries. J Burn Care Res 30: 471
[30]Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108: 985
[31]Occleston NL, Laverty HG, O’Kane S, Ferguson MWJ (2008) Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGF3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci, Polym Ed 19: 1047–1063
[32]Tsou R, Fathke C, Wilson L, Wallace K, Gibran N, Isik F (2002) Retroviral delivery of dominant-negative vascular endothelial growth factor receptor type 2 to murine wounds inhibits wound angiogenesis. Wound Repair Regen 10: 222–229
[33]Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am Journal Pathol
152:1445
[34]Nagy JA, Dvorak AM, Dvorak HF (2007)VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2: 251–275
[35]Hopf HW, Gibson JJ, Angeles AP, Constant JS, Feng JJ, Rollins MD, Zamirul Hussain M, Hunt TK (2005) Hyperoxia and angiogenesis. Wound Repair Regen 13: 558–564
[36]Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845
[37]Packer L, Fuehr K (1977) Low oxygen concentration extends the lifespan of cultured human diploid cells. Nature 267: 423–425
[38]Gawronska B, Bogacki M, Rim JS, Monroe WT, Manuel JA (2006) Scarless skin repair in immunodeficient mice. Wound Repair Regen 14: 265–276
[39]Guo S, DiPietro LA (2010) Factors affecting wound healing. J Dent Res 89: 219
[40]Park JE, Barbul A (2004) Understanding the role of immune regulation in wound healing. Am J Surg 187:S11S16
[41]Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL (2002) A role for skin gamma delta T cells in wound repair. Science 296: 747
[42]Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM (2008) Defects in skin {gamma}{delta} T cell function contribute to delayed wound repair in ra- pamycin-treated mice. J Immunol 181: 3974
[43]Santoro MM, Gaudino G (2005) Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 304: 274–286
[44]Martin P (1997) Wound healing–aiming for perfect skin regeneration. Science 276: 75–81
[45]Oshima H, Rochat A, Kedzia C, Kobayashi K, Barrandon Y (2001) Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell 104: 233–245
[46]Taylor G, Lehrer MS, Jensen PJ, Sun TT, Lavker RM (2000) Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell
102:451–461
336
Wound healing
[47]Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature
453:314–321
[48]Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, Cotsarelis G (2005) Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med 11: 1351–1354
[49]Levy V, Lindon C, Harfe BD, Morgan BA (2005) Distinct stem cell populations regenerate the follicle and interfollicular epidermis. Dev Cell 9: 855–861
[50]Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, Cotsarelis G (2007) Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 447: 316–320
[51]Wodarz A, Nusse R (2003) Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59
[52]Toy LW (2005) Matrix metalloproteinases: their function in tissue repair. Jo Wound Care 14: 20–22
[53]Lawrence WT (1998) Physiology of the acute wound. Clin Plast Surg 25: 321
[54]Peled ZM, Phelps ED, Updike DL, Chang J, Krummel TM, Howard EW, Longaker MT (2002) Matrix metalloproteinases and the ontogeny of scarless repair: the other side of the wound healing balance. Plast Reconst Surg 110: 801
[55]Dang C (2003) Fetal wound healing current perspectives. Clin Plast Surg 30(1): 13–23
[56]Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, Isik F (2004) Contribution of bone marrow–de- rived cells to skin: collagen deposition and wound repair. Stem Cells 22: 812–822
[57]Brittan M, Braun KM, Reynolds LE, Conti FJ, Reynolds AR, Poulsom R, Alison MR, Wright NA, Hodivala-Dilke KM (2005) Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion. J Pathol 205: 1–13
[58]Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Murad F, Zhao RCH (2005) Engrafted bone marrowderived Flk-1+ mesenchymal stem cells regenerate skin tissue. Tissue engineering 11: 110–119
[59]Wu Y, Chen L, Scott PG, Tredget EE (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648–2659
[60]Chen L, Tredget EE, Wu PYG, Wu Y (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3: 1886
[61]Kwon DS, Gao X, Liu, YB, Dulchavsky DS, Danyluk AL, Bansal M, Chopp M, McIntosh K, Arbab AS, Dulchavsky SA (2008) Treatment with bone marrownderived stromal cells accelerates wound healing in diabetic rats. Int Wound J 5: 453–463
[62]Suh W, Kim KL, Kim JM, Shin IS, Lee YS, Lee JY, Jang HS, Lee JS, Byun J, Choi JH (2005) Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/ macrophages and neovascularization. Stem Cells
23:1571–1578
[63]Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M (2009) Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 104(9): 1095–1102
[64]Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71
[65]Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA, Ghahary A, Tredget EE (2005) Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 13: 398–404
[66]Wang JF, Dodd C, Shankowsky HA, Scott PG, Tredget EE (2008) Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest 88: 1278–1290
[67]Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S (2005) Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Expl Cell Res 304: 81–90
[68]Yagmur C, Akaishi S, Ogawa R, Guneren E (2010) Mechanical receptor-related mechanisms in Scar management: a review and hypothesis. Plast Reconst Surg 126: 426
[69]Souba WW, Fink MP, Jurkovich GJ, Kaiser LP, Pearce WH, Pemberton JH, Soper aNJ (2007) ACS surgery: principles & practice, 6th edn. WebMD Professional Publishing
[70]Ueno C, Hunt TK, Hopf HW (2006) Using physiology to improve surgical wound outcomes. Plast Reconst Surg 117: 59S
[71]Robson MC (1997) Wound infection: a failure of wound healing Caused by an imbalance of bacteria. Surg Clin North Am 77: 637–650
[72]Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF (2007) Impaired wound healing. Clin Dermatol 25: 19–25
[73]Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF (1999) Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 134: 36
[74]Jeschke MG, Herndon DN, Ebener C, Barrow RE, Jauch KW (2001) Nutritional intervention high in vitamins, protein, amino acids, and {omega} 3 fatty acids improves protein metabolism during the hypermetabolic state after thermal injury. Arch Surg 136: 1301
[75]Desneves KJ, Todorovic BE, Cassar A, Crowe TC (2005) Treatment with supplementary arginine, vitamin C and zinc in patients with pressure ulcers: a randomised controlled trial. Clin Nutr 24: 979–987
[76]Williams JZ, Abumrad NN, Barbul A (2002) Effect of a specialized amino acid mixture on human collagen synthesis. Ann Surg 236: 369–374
[77]Williams FN, Herndon DN, Kulp GA (2010)Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery 149(2): 231–239
337
D. A. Brown, N. S. Gibran
[78]Demling RH, Orgill DP (2000) The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 15: 12–17
[79]Pham TN, Klein MB, Gibran NS, Arnoldo BD, Gamelli RL, Silver GM, Jeschke MG, Finnerty CC, Tompkins RG, Herndon DN (2008) Impact of oxandrolone treatment on acute outcomes after severe burn injury. Injury 2: 4
[80]Wicke C, Halliday B, Allen D, Roche NS, Scheuenstuhl H, Spencer MM, Roberts AB, Hunt TK (2000) Effects of steroids and retinoids on wound healing. Arch Surg
135:1265
[81]Nathens AB, Neff MJ, Jurkovich GJ (2003) Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Nutr Clin Pract 18: 264
[82]Fernandez-Madrid F, Prasad AS, Oberleas D (1973) Effect of zinc deficiency on nucleic acids, collagen, and noncollagenous protein of the connective tissue. J Lab Clin Med 82: 951
[83]Andrews M, Gallagher-Allred C (1999) The role of zinc in wound healing. Adv Skin Wound Care 12: 137
[84]Macon WL, Pories WJ (1971) The effect of iron deficiency anemia on wound healing. Plast Reconst Surg
48:399
[85]Sengupta A, Lichti UF, Carlson BA, Ryscavage AO, Gladyshev VN, Yuspa SH, Hatfield DL, Cobine P (2010) Selenoproteins are essential for proper keratinocyte function and skin development. PloS one 5: 199–209
[86]Colwell AS, Phan TT, Kong W, Longaker MT, Lorenz PH (2005) Hypertrophic scar fibroblasts have increased
connective tissue growth factor expression after transforming growth factor-[beta] stimulation. Plast Reconst Surg 116: 1387
[87]Lu L, Saulis AS, Liu WR, Roy NK, Chao JD, Ledbetter S, Mustoe TA (2005) The temporal effects of anti-TGF- [beta] 1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar Formation. J Am Coll Surg
201:391–397
[88]Tuan TL, Nichter LS (1998) The molecular basis of keloid and hypertrophic scar formation. Mol MedToday
4:19–24
[89]Ladwig GP, Robson MC, Liu R, Kuhn M, Muir DF, Schultz GS (2002) Ratios of activated matrix metalloproteinasen9 to tissue inhibitor of matrix metalloproteinasen1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen
10:26–37
[90]Copcu E (2009) Marjolin’s ulcer: a preventable complication of burns? Plast Reconst Surg 124: 156e
[91]Senarath-Yapa K, Enoch S (2009) Management of burns in the community. Wounds UK 5: 1–7
[92]Demling RH, DeSanti L (2010) Managing the burn wound. Burnsurgery.org. 11 December 2010 > http:// burnsurgery.org >
Correspondence: Nicole S. Gibran, M.D., Director, UW Burn Center; Professor, Department of Surgery, Harborview Medical Center, Box 359 796, 325 Ninth Avenue, Seattle, WA 98 104, USA, E-mail: nicoleg@u.washington.edu
338